Pharming Group N.V. - ADR Forecast, price target & analysts
$8.51
0.00%
day before yesterday
Nasdaq,
Apr 28, 03:30 pm CET
Pharming Group N.V. - ADR Target price 2025 - Analyst rating & recommendation
Powered by
Pharming Group N.V. - ADR Classifications & Recommendation:
Buy
100%
Pharming Group N.V. - ADR Price Target
| Target Price | $24.84 |
| Price | $8.51 |
| Potential |
191.92%
register free of charge
|
| Number of Estimates | 7 |
|
7 Analysts have issued a price target Pharming Group N.V. - ADR 2026 .
The average Pharming Group N.V. - ADR target price is $24.84.
This is
191.92%
register free of charge
$39.00
358.28%
register free of charge
$15.12
77.64%
register free of charge
|
|
| A rating was issued by 7 analysts: 7 Analysts recommend Pharming Group N.V. - ADR to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Pharming Group N.V. - ADR stock has an average upside potential 2026 of
191.92%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
Create a premium account to unlock analyst estimates.
Learn more
Powered by
Quarter
Annually
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 296.68 | 316.74 |
| 20.75% | 6.76% | |
| EBITDA Margin | 2.48% | 1.28% |
| 155.21% | 48.40% |
6 Analysts have issued a sales forecast Pharming Group N.V. - ADR 2025 . The average Pharming Group N.V. - ADR sales estimate is
$317m
Unlock
6.79%
higher
Unlock
$334m
12.48%
Unlock
$290m
2.18%
Unlock
This results in the following potential growth metrics:
4 Analysts have issued an Pharming Group N.V. - ADR EBITDA forecast 2025. The average Pharming Group N.V. - ADR EBITDA estimate is
$4.1m
Unlock
23.60%
lower
Unlock
$73.3m
1,277.34%
Unlock
$-47.8m
998.50%
Unlock
This results in the following potential growth metrics and future EBITDA Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
Create a premium account to unlock analyst estimates.
Learn more
Powered by
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| EV/Sales | 1.65 |
Current Pharming Group N.V. - ADR Upgrades & Downgrades
Create a Premium account to unlock Upgrades/Downgrades.
Learn more
| Analyst | Rating | Action | Date |
|---|---|---|---|
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| PORTZAMPARC BNP PARIBAS |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| JEFFERIES |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
| OPPENHEIMER & CO., INC. |
Locked
➜
Locked
|
Locked | Dec 15 2024 |
| FIRST BERLIN EQUITY RESEARCH |
Locked
➜
Locked
|
Locked | Dec 02 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Apr 02 2025 |
|
Locked
PORTZAMPARC BNP PARIBAS:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
JEFFERIES:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
Mar 12 2025 |
|
Locked
OPPENHEIMER & CO., INC.:
Locked
➜
Locked
|
Dec 15 2024 |
|
Locked
FIRST BERLIN EQUITY RESEARCH:
Locked
➜
Locked
|
Dec 02 2024 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
